Other Events ·
Cadrenal Therapeutics, Inc. announced a strategic realignment of its clinical portfolio into a Cardiac Acute Critical…
CVKDCadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. announced a strategic realignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise, initiating a structured process to secure out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets, including CAD-1005, frunexian, and tecarfarin. The company is transitioning to a partnership-driven business model to maximize asset value and commercialization paths. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing specialized therapies for critical care cardiology and orphan cardiovascular conditions.